Kalvista Pharmaceuticals Stock EBITDA

KALV Stock

USD 12.49 0.11 0.87%

Kalvista Pharmaceuticals fundamentals help investors to digest information that contributes to Kalvista Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kalvista Stock. The fundamental analysis module provides a way to measure Kalvista Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kalvista Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	EBITDA	-120.9 M	-114.8 M

EBITDA is likely to climb to about (114.8 M) in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kalvista Pharmaceuticals Company EBITDA Analysis

Kalvista Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Kalvista Pharmaceuticals EBITDA

(134.28 M)

Most of Kalvista Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kalvista Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Kalvista EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Kalvista Pharmaceuticals is extremely important. It helps to project a fair market value of Kalvista Stock properly, considering its historical fundamentals such as EBITDA. Since Kalvista Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kalvista Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kalvista Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.4	-0.63	-0.82	0.76	-0.21	1.0	-0.52	0.8	0.36	0.7	0.78	0.68	0.86	0.77	-0.09	0.19	0.82	0.82	0.48
Total Stockholder Equity	0.99		0.44	-0.63	-0.79	0.74	-0.33	0.99	-0.55	0.82	0.34	0.76	0.77	0.68	0.87	0.78	-0.12	0.16	0.83	0.83	0.49
Current Deferred Revenue	0.4	0.44		-0.78	-0.28	0.34	-0.41	0.41	-0.82	0.41	-0.56	0.14	0.31	0.5	0.5	0.46	0.46	-0.73	0.36	0.38	0.3
Net Debt	-0.63	-0.63	-0.78		0.43	-0.4	0.19	-0.63	0.79	-0.56	0.26	-0.29	-0.6	-0.72	-0.66	-0.59	-0.47	0.45	-0.46	-0.47	-0.28
Retained Earnings	-0.82	-0.79	-0.28	0.43		-0.95	0.03	-0.81	0.31	-0.83	-0.35	-0.6	-0.55	-0.49	-0.51	-0.71	0.11	-0.22	-0.63	-0.63	-0.61
Accounts Payable	0.76	0.74	0.34	-0.4	-0.95		-0.09	0.75	-0.35	0.83	0.26	0.59	0.39	0.44	0.4	0.61	-0.08	0.13	0.6	0.59	0.63
Total Liab	-0.21	-0.33	-0.41	0.19	0.03	-0.09		-0.21	0.36	-0.39	0.12	-0.54	-0.21	-0.25	-0.33	-0.2	0.26	0.2	-0.32	-0.32	-0.24
Total Current Assets	1.0	0.99	0.41	-0.63	-0.81	0.75	-0.21		-0.53	0.8	0.36	0.7	0.77	0.67	0.86	0.77	-0.09	0.18	0.82	0.83	0.48
Short Term Debt	-0.52	-0.55	-0.82	0.79	0.31	-0.35	0.36	-0.53		-0.55	0.2	-0.34	-0.46	-0.67	-0.56	-0.63	-0.29	0.45	-0.36	-0.38	-0.18
Common Stock	0.8	0.82	0.41	-0.56	-0.83	0.83	-0.39	0.8	-0.55		0.36	0.79	0.58	0.59	0.56	0.66	-0.11	0.14	0.76	0.76	0.73
Long Term Debt	0.36	0.34	-0.56	0.26	-0.35	0.26	0.12	0.36	0.2	0.36		0.6	0.35	0.22	0.23	0.33	-0.6	0.96	0.4	0.38	0.25
Long Term Debt Total	0.7	0.76	0.14	-0.29	-0.6	0.59	-0.54	0.7	-0.34	0.79	0.6		0.56	0.65	0.59	0.69	-0.31	0.46	0.68	0.68	0.48
Capital Surpluse	0.78	0.77	0.31	-0.6	-0.55	0.39	-0.21	0.77	-0.46	0.58	0.35	0.56		0.79	0.91	0.73	-0.15	0.19	0.67	0.67	0.32
Property Plant Equipment	0.68	0.68	0.5	-0.72	-0.49	0.44	-0.25	0.67	-0.67	0.59	0.22	0.65	0.79		0.77	0.88	0.2	0.04	0.5	0.51	0.24
Net Tangible Assets	0.86	0.87	0.5	-0.66	-0.51	0.4	-0.33	0.86	-0.56	0.56	0.23	0.59	0.91	0.77		0.75	-0.08	0.07	0.77	0.78	0.33
Net Receivables	0.77	0.78	0.46	-0.59	-0.71	0.61	-0.2	0.77	-0.63	0.66	0.33	0.69	0.73	0.88	0.75		0.04	0.15	0.52	0.52	0.26
Deferred Long Term Liab	-0.09	-0.12	0.46	-0.47	0.11	-0.08	0.26	-0.09	-0.29	-0.11	-0.6	-0.31	-0.15	0.2	-0.08	0.04		-0.63	-0.23	-0.21	-0.17
Short Long Term Debt	0.19	0.16	-0.73	0.45	-0.22	0.13	0.2	0.18	0.45	0.14	0.96	0.46	0.19	0.04	0.07	0.15	-0.63		0.24	0.22	0.13
Net Invested Capital	0.82	0.83	0.36	-0.46	-0.63	0.6	-0.32	0.82	-0.36	0.76	0.4	0.68	0.67	0.5	0.77	0.52	-0.23	0.24		1.0	0.8
Net Working Capital	0.82	0.83	0.38	-0.47	-0.63	0.59	-0.32	0.83	-0.38	0.76	0.38	0.68	0.67	0.51	0.78	0.52	-0.21	0.22	1.0		0.8
Capital Stock	0.48	0.49	0.3	-0.28	-0.61	0.63	-0.24	0.48	-0.18	0.73	0.25	0.48	0.32	0.24	0.33	0.26	-0.17	0.13	0.8	0.8

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Kalvista Pharmaceuticals

Ebitda Over Time

Kalvista Ebitda

Ebitda

(114.81 Million)

Kalvista Pharmaceuticals reported EBITDA of (120.85 Million) in 2024

According to the company disclosure, Kalvista Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (134.28 Million). This is 115.3% lower than that of the Biotechnology sector and 234.07% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.44% higher than that of the company.

Kalvista EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kalvista Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kalvista Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kalvista Pharmaceuticals by comparing valuation metrics of similar companies.

Kalvista Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Kalvista Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kalvista Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kalvista Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Kalvista Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Kalvista Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kalvista Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kalvista Pharmaceuticals' value.

		Shares
Octagon Capital Advisors Lp	2023-12-31	1.4 M
Woodline Partners Lp	2024-12-31	1.3 M
Stempoint Capital Lp	2024-12-31	992.8 K
Emerald Advisers, Llc	2024-12-31	836 K
Geode Capital Management, Llc	2024-12-31	822.4 K
Dafna Capital Management Llc	2024-12-31	811.7 K
Schroder Investment Management Group	2024-12-31	805.4 K
Dimensional Fund Advisors, Inc.	2024-12-31	696 K
Silverarc Capital Management, Llc	2024-12-31	612.2 K
Vr Adviser, Llc	2024-12-31	6.2 M
Suvretta Capital Management, Llc	2024-12-31	4.9 M

Kalvista Fundamentals

	Return On Equity	-1.5
	Return On Asset	-0.58
	Current Valuation	375.74 M
	Shares Outstanding	49.42 M
	Shares Owned By Insiders	1.36 %
	Shares Owned By Institutions	98.64 %
	Number Of Shares Shorted	5.83 M
	Price To Earning	(2.82) X
	Price To Book	4.29 X
	Price To Sales	107.42 X
	Gross Profit	(81.07 M)
	EBITDA	(134.28 M)
	Net Income	(126.64 M)
	Cash And Equivalents	142.08 M
	Cash Per Share	5.78 X
	Total Debt	7.32 M
	Debt To Equity	0.05 %
	Current Ratio	17.51 X
	Book Value Per Share	2.93 X
	Cash Flow From Operations	(89.23 M)
	Short Ratio	12.75 X
	Earnings Per Share	(3.77) X
	Target Price	26.33
	Number Of Employees	150
	Beta	0.76
	Market Capitalization	622.67 M
	Total Asset	235.4 M
	Retained Earnings	(469.73 M)
	Working Capital	202.88 M
	Current Asset	54.95 M
	Current Liabilities	4.27 M
	Net Asset	235.4 M

About Kalvista Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kalvista Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kalvista Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kalvista Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC